sgi-1776
Small moleculeexperimental
Clinical trial activity
2 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Feb 1, 2009 (NCT00848601)
Timeline
2000s
- Jan 1, 2009
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Serine/threonine-protein kinase PIMINHIBITOR
Serine/threonine-protein kinase PIM inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
CN1CCC(CNc2ccc3ncc(-c4cccc(OC(F)(F)F)c4)n3n2)CC1- Mol. weight
- 405.42 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL1952329 ↗
Also known as
- sgi1776
- sgi 1776
- sgi-1776
- sgi-1776
- sgi-1776
- sgi-1776
- sgi-1776
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01239108 | Phase 1 | Oct 1, 2010 | Astex Pharmaceuticals, Inc. |
| NCT00848601 | Phase 1 | Feb 1, 2009 | Astex Pharmaceuticals, Inc. |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Astex Pharmaceuticals, Inc. | For profit | 2 | 2 | 1 | 2009 |
1 organizations
Page 1 / 1